## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.7% below STRENGTH zone (3.0-6.0%); PEG 1.94 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($241.01)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Labcorp Takes Strategic Stake in RNA Diagnostics Firm**
- Source: AD HOC NEWS | 20251217T020827 | Somewhat-Bullish | Relevance: 100%
- Labcorp has made a strategic investment in Cofactor Genomics, partnering with Ascension Ventures, to accelerate the expansion of Cofactor's RNA-based diagnostic tools. This move aims to broaden the commercial reach of Cofactor's OncoPrism test, which predicts patient immune responses to immunotherapy. The investment aligns with Labcorp's initiative to enhance advanced diagnostics and precision medicine offerings.

**2. LabCorp Holdings Inc. (LH) Files Form 8-K with SEC**
- Source: GuruFocus | 20251216T012500 | Neutral | Relevance: 100%
- LabCorp Holdings Inc. (LH) has filed a Form 8-K with the SEC on December 9, 2025, to disclose significant company developments. Although specific details of the filing were not provided in this release, such reports typically announce material events like mergers, leadership changes, or other financial or operational impacts. Investors are encouraged to review the full document on the SEC's website for complete information.

**3. Is There Now An Opportunity In Labcorp Holdings Inc. (NYSE:LH)?**
- Source: 富途牛牛 | 20251216T000807 | Somewhat-Bullish | Relevance: 98%
- Labcorp Holdings Inc. (NYSE:LH) has experienced significant price movements, rising to US$291 before dropping to US$247, and is currently trading at US$264. The company's share price appears reasonably valued compared to industry peers, with a P/E ratio slightly above the industry average. Future earnings are expected to increase by 58%, suggesting a highly optimistic outlook.

**4. St. Louis biotech Cofactor Genomics lands investments from Labcorp, Ascension Ventures**
- Source: The Business Journals | 20251216T203043 | Somewhat-Bullish | Relevance: 92%
- Cofactor Genomics, a St. Louis-based biotech company, has secured new investments from Labcorp and Ascension Ventures. This funding will support the expansion of its technology, which aims to help doctors predict which cancer patients will respond most effectively to immunotherapy treatments.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.5% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.4M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.94 elevated, pricing in significant growth expectations. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.9B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.94 |
| Forward P/E | 14.4 |
| Current P/E | 15.4 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.7% to -1.7% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.7pp (needs >3.0% for momentum thesis). Below SMA200 (0.98x), long-term trend not supportive. MACD histogram bearish (-0.83), momentum weakening. OFD pattern: -MTH (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.72% (CS: 20) | Neutral |
| RSI_14 | 35.4 | Neutral |
| MACD Histogram | -0.83 | Bearish |
| vs SMA20 | 0.959x | Below |
| vs SMA50 | 0.947x | Below |
| vs SMA200 | 0.978x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $251.97
- **Stop Loss:** $241.01 (4.3% risk)
- **Target:** $262.93 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 86
- **Position Value:** $21,669.42
- **Portfolio %:** 21.67%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*